ESPE Abstracts

Background: The NPR2 gene plays a critical role in the human growth plate. Pathogenic NPR2 variants can result in varying degrees of short stature. The majority of subjects have no specific clinical findings and are likely classified as idiopathic short stature.Objective: To describe the phenotypic spectrum, analyze genotype-phenotype correlations and assess the response and safety of growth hormone (GH...

Background: The genetic etiology of SGA-SS spans from abnormalities of the GH-IGF-1 axis, growth plate disorders, and defective fundamental intracellular/intranuclear processes, to imprinting conditions. We recently elucidated the genetic etiology in a large cohort of 74 children SGA-SS (Toni L et al, Horm Res Pediat 2024; 97(1): 40-52). Of these, 49 have already completed five years of daily GH therapy.Aim: To analyze 5...

Introduction: Growth hormone (GH) is essential for stimulating growth and cell proliferation through its effects on metabolism, cartilage and bone growth. We have conducted initial studies to find new biomarkers for GH deficiency and early treatment response, focusing on miRNAs expressed in both sexes. We aimed at investigating sex-specific differences in circulating miRNAs at baseline and after 3 months on GH treatment in a cohort of prepubertal children with...

Context: In the diagnosis of permanent GH deficiency (GHD) during the transition phase, the 2019 AACE guidelines recommended peak GH-cutoffs of ≤3µg/L and ≤1µg/L for the glucagon test (GST), while a recent investigation identified a value <5.8μg/L as a suitable gold standard (Fava et al, Journal of Clinical Endocrinology and Metabolism, 2024). However, the clinical applicability of this cutoff remains to be confirmed and the potential c...

Background: The diagnosis of GH deficiency is challenged by the suboptimal accuracy of GH stimulation tests. Overnight GH sampling (OGS) may be useful in the diagnosis of growth disorders.Objectives: To establish if 1) the reduced number of spontaneous overnight GH profile peaks (SOGPP) is associated with hypothalamo-pituitary (H-P) abnormalities on MRI, 2) these children benefit from GH treatment....

Background: LUM-201, a potent long-acting oral GH secretagogue (GHS), acts on the GHS Receptor-1a to induce GH secretion. The best candidates for this investigative oral treatment are pre-pubertal children with moderate GHD (standard stimulation testing peak GH between ≥3 <10ng/ml) that respond positively to the LUM-201 Predictive Enrichment Marker (PEM) test (Bright et al JES, 2021). PEM positive responders have basal serum IGF-1 >30ng/ml and a peak ...